Tr1X is developing a proprietary pipeline of allogeneic engineered Treg and CAR‑Treg cell therapies to treat major autoimmune and inflammatory diseases. The company’s lead program is an investigational Tr1 cell therapy, TRX103, planned for a Phase 1 trial to prevent Graft versus Host Disease (GvHD) in patients undergoing mismatched hematopoietic stem cell transplant. Tr1X is also advancing additional programs targeting inflammatory bowel disease, Type 1 diabetes and multiple B‑cell mediated autoimmune diseases. The company raised $75M in a Series A to enable immediate and expedited execution of its pipeline. Leadership updates accompanying the raise include William Lis as CEO and Director and Maria Grazia Roncarolo, M.D., as President and Head of R&D and Director; Tao Fu and Katherine A. High, M.D., were named Independent Directors. The company is based in San Diego, CA.

Total raised

$75M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2024